Crinetics Pharmaceuticals, Inc. Quarterly Common Stocks, Including Additional Paid in Capital in USD from Q4 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of par value plus amounts in excess of par value or issuance value for common stock issued.
Summary
Crinetics Pharmaceuticals, Inc. quarterly Common Stocks, Including Additional Paid in Capital history and growth rate from Q4 2018 to Q3 2024.
  • Crinetics Pharmaceuticals, Inc. Common Stocks, Including Additional Paid in Capital for the quarter ending September 30, 2024 was $1.7B, a 49% increase year-over-year.
Common Stocks, Including Additional Paid in Capital, Quarterly (USD)
Common Stocks, Including Additional Paid in Capital, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $1.7B +$560M +49% Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $1.63B +$834M +105% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $1.6B +$827M +108% Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $1.19B +$432M +56.9% Dec 31, 2023 10-Q 2024-11-12
Q3 2023 $1.14B +$392M +52.2% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $792M +$49.9M +6.73% Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $768M +$153M +24.9% Mar 31, 2023 10-Q 2023-05-09
Q4 2022 $759M +$152M +25% Dec 31, 2022 10-K 2024-02-28
Q3 2022 $751M +$313M +71.3% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $742M +$324M +77.5% Jun 30, 2022 10-Q 2022-08-12
Q1 2022 $615M +$275M +80.9% Mar 31, 2022 10-Q 2022-05-12
Q4 2021 $608M +$271M +80.6% Dec 31, 2021 10-K 2023-02-28
Q3 2021 $438M +$105M +31.5% Sep 30, 2021 10-Q 2021-11-05
Q2 2021 $418M +$87.7M +26.6% Jun 30, 2021 10-Q 2021-08-10
Q1 2021 $340M +$121M +54.9% Mar 31, 2021 10-Q 2021-05-06
Q4 2020 $337M +$126M +59.6% Dec 31, 2020 10-K 2022-03-30
Q3 2020 $333M +$125M +59.7% Sep 30, 2020 10-Q 2020-11-06
Q2 2020 $330M +$124M +59.8% Jun 30, 2020 10-Q 2020-08-07
Q1 2020 $219M +$14.8M +7.23% Mar 31, 2020 10-Q 2020-05-08
Q4 2019 $211M +$7.25M +3.56% Dec 31, 2019 10-K 2021-03-30
Q3 2019 $209M Sep 30, 2019 10-Q 2019-11-12
Q2 2019 $207M Jun 30, 2019 10-Q 2019-08-13
Q1 2019 $205M Mar 31, 2019 10-Q 2019-05-13
Q4 2018 $204M Dec 31, 2018 10-K 2020-03-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.